GlassScriptPhysician profile
Tamara S Hunter
NPI 1912285008
$1,728.60
in general payments reported to CMS, 2019-2025
18 companies · $939 in 2025
The $939 reported for 2025 was more than what 84% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $19.28 · 2024: $770 · 2025: $939.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,695 · Education: $34.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,694.60 |
| Education | $34.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $457.62 | 2024-2025 | |
| Astrazeneca Pharmaceuticals LP | $295.97 | 2024-2025 | Tezspire, Fasenra, Airsupra |
| Ars Pharmaceuticals Operations, INC. | $164.48 | 2025 | Neffy |
| Amgen INC. | $115.55 | 2024-2025 | Tezspire |
| Novartis Pharmaceuticals Corporation | $110.49 | 2023-2025 | |
| Grifols USA, LLC | $99.60 | 2024-2025 | Xembify |
| Regeneron Healthcare Solutions, INC. | $78.85 | 2024-2025 | Dupixent |
| Pfizer INC. | $70.75 | 2024-2025 | |
| Glaxosmithkline, LLC. | $61.31 | 2024-2025 | Nucala, Trelegy Ellipta |
| Octapharma USA, INC. | $48.22 | 2024-2025 | Cutaquig |
| Takeda Pharmaceuticals U.S.A., INC. | $47.27 | 2024 | Cuvitru, Eohilia |
| Optinose US, INC. | $33.14 | 2024 | |
| Csl Behring | $30.88 | 2025 | Hizentra |
| Pharming Healthcare, INC. | $27.60 | 2024 | Ruconest |
| Dermavant Sciences, INC. | $23.88 | 2024 | Vtama |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kedrion Biopharma, INC. | $23.15 | 2025 | Koate, Kedrab, Gammaked |
| Blueprint Medicines Corporation | $21.11 | 2024 | Ayvakit |
| Kaleo, INC. | $18.73 | 2024 | Auvi-Q |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tamara Hunter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.